WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

The IWBS show floor is almost full — take a look for yourself or secure your booth space today! → Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Autolus Therapeutics plc

< Previous 1 2 3 4 Next >
News headline image
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL CAH
News headline image
Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics to Host Virtual Capital Markets Day
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics Announces Publication in Molecular Therapy
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics announces resignation of Chief Financial Officer
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics Has No Business Relationship with Silicon Valley Bank
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics announces Board changes
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL CABA
News headline image
Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Announces Pricing of Public Offering
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Announces Proposed Public Offering in the United States
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics announces handover of first clean rooms of new Stevenage, UK, manufacturing facility
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational Progress
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
News headline image
Moderna exercises option to license proprietary targeting technology from Autolus
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL MRNA
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.